EVFM Evofem Biosciences, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1618835 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-0.0%
TTM net income YoY-133.9%
TTM EPS YoY-150.0%
Revenue 3-yr CAGR9.3%
Net income 3-yr CAGR—
Margins
Gross margin75.9%
Operating margin-16.8%
Net margin-71.7%
FCF margin—
EBITDA margin-16.7%
Returns
ROE—
ROA-120.6%
ROIC (approx.)—
Asset turnover1.68x
Leverage & solvency
Liabilities / assets1,184.7%
Debt / equity—
Current ratio0.07x
Interest coverage-1.18x
Cash quality & payout
Operating cash flow / net income0.05x
Accruals ratio-115.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $20.18M | $19.36M | $18.22M | $16.84M | $8.24M |
| Cost of revenue | $4.62M | $3.83M | $6.51M | $4.42M | $4.05M |
| Gross profit | $15.57M | $15.53M | $11.71M | $12.42M | $4.19M |
| R&D expense | — | $1.84M | $2.94M | $25.03M | $33.13M |
| SG&A expense | $7.39M | $11.56M | $14.95M | $27.56M | $24.71M |
| Operating income | $3.37M | -$7.68M | -$17.85M | -$84.12M | -$166.80M |
| Interest expense | $2.37M | $2.24M | $2.27M | $2.18M | $2.67M |
| Pretax income | $393,000 | -$8.86M | $53.00M | -$76.65M | -$205.18M |
| Income tax | $2,000 | — | $17,000 | $44,000 | $17,000 |
| Net income | $391,000 | -$8.86M | $52.98M | -$76.70M | -$205.19M |
| EBITDA | $3.39M | -$7.65M | -$17.37M | -$83.11M | -$165.78M |
| EPS (basic) | 0.00 | -0.11 | 10.36 | -167.42 | -23.63 |
| EPS (diluted) | 0.00 | -0.11 | 0.05 | -167.42 | -23.63 |
| Weighted avg. shares (diluted) | 6.42B | 80.00M | 984.04M | 465,967 | 8.73M |
| Balance sheet | |||||
| Cash & equivalents | $578,000 | $741,000 | $580,000 | $4.78M | $13.59M |
| Receivables | $12.48M | $9.83M | $5.74M | $1.13M | $6.45M |
| Inventory | $1.13M | $1.58M | $1.70M | $5.38M | $7.67M |
| Current assets | $15.28M | $13.61M | $9.21M | $12.70M | $30.14M |
| PP&E, net | $418,000 | $458,000 | $1.20M | $3.94M | $5.77M |
| Intangibles | $4.35M | $9.60M | — | — | — |
| Total assets | $20.27M | $23.79M | $10.55M | $25.16M | $42.51M |
| Current liabilities | $84.82M | $80.45M | $72.46M | $93.83M | $137.66M |
| Short-term debt | $147,000 | $135,000 | — | — | — |
| Total liabilities | $89.71M | $90.26M | $72.47M | $96.96M | $142.09M |
| Shareholders' equity | -$74.34M | -$71.26M | -$66.51M | -$71.80M | -$104.31M |
| Shares outstanding | 126.69M | 113.36M | 20.01M | 984,786 | 10.83M |
| Cash flow statement | |||||
| Operating cash flow | -$1.99M | -$3.88M | -$8.97M | -$70.41M | -$146.67M |
| Capital expenditure | $5,000 | $14,000 | $4,000 | $341,000 | $2.94M |
| Free cash flow | -$2.00M | -$3.90M | -$8.97M | -$70.75M | -$149.61M |
| Investing cash flow | -$62,000 | -$569,000 | -$4,000 | -$341,000 | -$2.69M |
| Financing cash flow | $1.89M | $4.62M | $4.78M | $61.94M | $90.69M |
| Depreciation & amortization | $19,000 | $30,000 | $477,000 | $1.01M | $1.02M |
| Stock-based compensation | $166,000 | $847,000 | $1.19M | $3.31M | $8.90M |
| Share buybacks | — | — | — | $18,000 | $0 |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.